EASD24: Eli Lilly’s Phase III Data on Once-Weekly Insulin for Diabetes Management
Tuesday, 10 September 2024, 13:05
Eli Lilly’s Promising Phase III Data
Recent data from the EASD24 conference highlighted Eli Lilly's innovative once-weekly insulin, efsitora. This groundbreaking insulin therapy showcased its capability to induce significant reductions in HbA1C levels, providing a strong alternative for diabetes management.
Clinical Trials Overview
- Trial A: Targeted type 1 diabetes patients.
- Trial B: Focused on individuals with type 2 diabetes.
Both trials confirmed that efsitora achieved HbA1C reductions similar to those seen with daily insulin administration, signaling a potential shift in diabetes treatment protocols.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.